National guidelines, therefore, reflect the design of those trials and the FDA approval of both drugs recommends adjuvant chemotherapy to patients with stage II–III NSCLC, EGFR mutant followed by 3 years of adjuvant osimertinib, whereas they advise to proceed straight to alectinib for 2 years in patients with ALK rearranged disease [86] (Table 3 and Table 4). The gene discussed is ALK; the disease is non-small cell lung carcinoma.